SEI Investments’s Aclaris Therapeutics ACRS Stock Holding History

SEI Investments’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$734K	Sell	138,778 -78,376	-36%	-$350K	﹤0.01%	2468
2026 Q1	$814K	Buy	+217,154	New	+$733K	﹤0.01%	2452
2025 Q2	–	Sell	-25,189	Closed	-$38.5K	–	2785
2025 Q1	$38.5K	Buy	+25,189	New	+$53.7K	﹤0.01%	2696
2019 Q2	–	Sell	-3,277	Closed	-$18K	–	2378
2019 Q1	$18K	Sell	3,277 -10,710	-77%	-$71K	﹤0.01%	2752
2018 Q4	$103K	Buy	13,987 +13,951	+38,753%	+$144K	﹤0.01%	2193
2018 Q3	$0	Buy	36 +35	+3,500%	+$600	﹤0.01%	2507
2018 Q2	$0	Sell	1 -1,048	-100%	-$19.4K	﹤0.01%	3599
2018 Q1	$18K	Buy	1,049 +169	+19%	+$3.58K	﹤0.01%	2676
2017 Q4	$22K	Sell	880 -7,391	-89%	-$180K	﹤0.01%	2573
2017 Q3	$214K	Sell	8,271 -2,769	-25%	-$74.2K	﹤0.01%	1853
2017 Q2	$300K	Buy	11,040 +10,663	+2,828%	+$290K	﹤0.01%	1771
2017 Q1	$11K	Sell	377 -2,223	-86%	-$64.1K	﹤0.01%	2441
2016 Q4	$71K	Buy	+2,600	New	+$66.3K	﹤0.01%	2043

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

SEI Investments's ACRS Position: Q2 2026 in Review

SEI Investments reduced its Aclaris Therapeutics (ACRS) stake by 36% in Q2 2026, selling an estimated $350K and leaving 138,778 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

SEI Investments first reported a position in ACRS in Q4 2016 and has held it in 13 quarters since. The position peaked at $814K in Q1 2026. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

SEI Investments held 138,778 shares of Aclaris Therapeutics worth $734K as of Q2 2026.
SEI Investments sold 78,376 Aclaris Therapeutics shares in Q2 2026, an estimated $350K.
Aclaris Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2468 holding.
SEI Investments first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 13 quarters since.
SEI Investments's Aclaris Therapeutics position peaked at $814K in Q1 2026.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.